How flow chemistry is opening the way to new forms of portable API synthesis.

Marathon sells Emflaza, but questions remain about FDA approval processes.

Small molecule APIs have been a strong focus throughout Bernhard Paul's career.

Can high density cryopreservation allow biopharma manufacturers to buy back time?

Pharma has a number of underlying structural issues. It's time for a change of direction.

Professor Lee Cronin shares his vision for the future of drug manufacturing.

Synthetic biology could help to re-write the rules of biopharma production.

Researchers develop a pharmacy on demand system using continuous chemical flow processing.

How close are we to the real-world implementation of drugs-on-demand technology?

India has held pharma’s interest for decades, but it is a challening market to work in.